Correlation of coreceptor usage and disease progression

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 432-439

  Verhofstede, Chris ^a   Nijhuis, Monique ^b   Vandekerckhove, Linos ^c  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CCR5; coreceptor; CXCR4; HIV; pathogenesis

Indexed keywords

ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; EMTRICITABINE; NEVIRAPINE; RITONAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ANTIRETROVIRUS THERAPY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRAL TROPISM; VIRUS LATENCY; VIRUS LOAD; VIRUS PATHOGENESIS;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; VIRAL TROPISM;

EID: 84865648373     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356f6f2     Document Type: Review

References (75)

1. Koyanagi Y, Miles S, Mitsuyasu RT, et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987; 236:819-822.
2. Sakai K, Ma XY, Volsky DJ. Low-cytopathic infectious clone of human immunodeficiency virus type-I (HIV-I). FEBS Lett 1988; 238:257-261.
3. Fenyo EM, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989; 3: S5-S12.
4. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6:49-54.
5. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4 cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
6. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993; 7:1035-1040.
7. Fenyo EM, Fiore J, Karlsson A, et al. Biological phenotypes of HIV-1 in pathogenesis and transmission. Antibiot Chemother 1994; 46:18-24.
8. Fiore JR, Bjorndal A, Peipke KA, et al. The biological phenotype of HIV-1 is usually retained during and after sexual transmission. Virology 1994; 204:297- 303.
9. Karlsson A, Parsmyr K, Aperia K, et al. MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 1994; 170:1367-1375.
10. Miedema F, Meyaard L, Koot M, et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994; 140:35-72.
11. Berger EA. HIV entry and tropism: The chemokine receptor connection. AIDS 1997; 11 (Suppl A): S3-S16.
12. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP- 1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
13. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4 cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
14. Bleul CC Farzan M Choe H et al. The lymphocyte chemoattractant SDF-1 is Ligand For LESTRfusin Blocks HIV-1 Entry. Nature 1996; 382829-833.
15. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382:833-835.
16. Shioda T, Levy JA, Chengmayer C. Macrophage and T-cell line tropisms of HIV-1 are determined by specific regions of the envelope Gp120 gene. Nature 1991; 349:167-169.
17. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
18. Simon B, Grabmeier-Pfistershammer K, Rieger A, et al. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 2010; 24:2051-2058.
19. Vandekerckhove LPR,WensingAMJ, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11:394- 407.
20. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
21. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
22. Zimmerman PA, BucklerWhite A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Molec Med 1997; 3:23-36.
23. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
24. Samson M, Libert F, Costagliola S, et al. Chemokine receptors and their role as HIV coreceptors. Naunyn-Schmiedebergs Arch Pharmacol 1998; 358:R192-R.
25. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-1181.
26. van 't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060-2067.
27. Eshleman SH, Husnik M, Hudelson S, et al. Antiretroviral drug resistance, HIV- 1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 2007; 21:1165-1174.
28. Huang W, Toma J, Stawiski E, et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 2009; 25:795-802.
29. Frange P, Chaix ML, Raymond S, et al. Low frequency of CXCR4-using viruses in patients at the time of primary nonsubtype-B HIV-1 infection. J Clin Microbiol 2010; 48:3487-3491.
30. Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: The French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64:135-141.
31. de Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59:698-704.
32. Rieder P, Joos B, Scherrer AU, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis 2012; 53:1271-1279. In this study patients were analyzed for coreceptor tropism and overall variability. For the vast majority of the viruses predicted as CXCR4-using based on the V3 sequence, the coreceptor tropism could not be confirmed in the phenotype analysis. These observations indicate that some of the differences in X4 and R5 prevalence data as reported by different studies are due to differences in the methodology used for tropism determination.
33. Nozza S, Canducci F, Galli L, et al. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. J Antimicrob Chemother 2011; 67:1224-1227. A well designed study showing that non-R5 viral tropism as defined by geno2- pheno is predictive of CD4 decrease, independent of the viral set point or CD4 county. This study underlines the independent relation between coreceptor tropism and disease progression.
34. Lin NH, Smeaton LM, Giguel F, et al. Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr 2011; 57:46-50.
35. Wilkin TJ, Goetz MB, Leduc R, et al. Reanalysis of coreceptor tropism in HIV- 1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2007; 52:925-928. Presents the results of retesting of samples from four different cohorts of HIV-1- infected patients that have been analyzed for coreceptor tropism with the original Trofile assay. Nine to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. The higher X4 detection rate of the enhanced sensitivity assay was most pronounced in the treatment-experienced population These findings illustrate the importance of test validation. 36. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
36. Chalmet K, Dauwe K, Foquet L, et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 2012; 205:174-184. The authors challenge the idea of a bottleneck favoring R5 transmission. Using phylogenetic analysis they were able to show that X4 strains can be present in transmission clusters and transmission pairs.
37. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866- 872.
38. Melby T, Despirito M, Demasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006; 194:238-246.
39. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1: infected patients with detectable viremia. J Infect Dis 2006; 194:926-930.
40. Coakley E, Benhamida J, Chappey C. An evaluation of tropism profiles and other characteristics among 3988 individuals screened from A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) studies for maraviroc. 2nd International Workshop on Targeting HIV Entry October 20-21, 2006; Boston, M.A.
41. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the Multicenter AIDS Cohort Study. J Infect Dis 2008; 198:1104-1112.
42. Poveda E, Briz V, de Mendoza C, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007; 79:1040-1046.
43. Goetz MB, Leduc R, Kostman JR, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2009; 50:259-266.
44. Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-1623.
45. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-U27.
46. Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5-and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 2011; 7. First detailed description of mutational pathways in V3 during the transition from CCR5 to CXCR4 in natural HIV-1 infection. The results show a stepwise mutational pathway involving sequential intermediate variants, which were generally present at relatively low frequencies compared with the major predicted CCR5 and CXCR4-using variants.
47. Jensen MA, Fukushima M, Davis RW. DMSO and Betaine greatly improve amplification of GC-rich constructs in de novo synthesis. PLoS One 2010; 5.
48. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-10502.
49. Ida S, Gatanaga H, Shioda T, et al. HIV type 1 V3 variation dynamics in vivo: long-term persistence of nonsyncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses 1997; 13:1597-1609.
50. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-celltropic virus population. J Virol 1992; 66:1354-1360.
51. Koot M, van 't Wout AB, Kootstra NA, et al. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996; 173:349-354.
52. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human-immunodeficiency-virus on disease progression. J Infect Dis 1994; 169:968-974.
53. Fouchier RAM Meyaard L Brouwer M et al. Broader tropism higher cytopathicity for CD4 T cells of a syncytium-inducing compared to Nonsyncytium-inducing HIV-1 Isolate As A Mechanism For Accelerated CD4 T Cell Decline In Vivo. Virology 1996; 21987-95.
54. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-628.
55. Koot M van Leeuwen R de Goede REY et al. Conversion rate towards Syncytium-inducing (SI) Phenotype During Different Stages Of Human Immunodeficiency Virus Type 1 Infection Prognostic Value Of SI Phenotype For Survival After AIDS Diagnosis. J Infect Dis 1999; 179254-258.
56. Maas JJJ, Gange SJ, Schuitemaker H, et al. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000; 14:1155- 1161.
57. Daar ES, Kesler L, Petropoulos J, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-649.
58. Soulie C, Marcelin AG, Ghosn J, et al. HIV-1 X4/R5 coreceptor in viral reservoir during suppressive HAART. AIDS 2007; 21:2243-2245.
59. Soulie C, Fourati S, Lambert-Niclot S, et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65:749-751.
60. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4:e5683.
61. McGovern R, Symons J, Poon A, et al. Longitudinal 'deep' sequence analysis of dual/mixed infected patients treated with maraviroc demonstrates rapid selection for X4-tropic virus with extremely low FPR. Antivir Ther 2011; 16:A97-A.
62. Brieu N, Portales P, Carles MJ, Corbeau P. Interleukin-7 induces HIV type 1 R5-to-X4 switch. Blood 2011; 117:2073-2074. The authors provide in-vitro evidence for the possible involvement of a host factor in the R5 to X4 switch process. They were able to show that IL-7 increases CD4 Tcell surface CXCR4 density, HIV-1 production and the risk of emergence of X4 strain. In contrast, HIV-1 production remained low in the absence of IL-7, and no X4 strains were detected. They hypothesize that increased CXCR4 density and higher replication enhance the selection of X4 variants.
63. Schreiber M, Wachsmuth C, Muller H, et al. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. J Gen Virol 1996; 77:2403-2414.
64. Balzarini J. Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 2005; 5:726-731.
65. Rusconi S, De Pasquale MP, Mainini F, et al. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Antivir Ther 1996; 1:211-219.
66. Katzenstein TL, Nielsen C, Bruun L, et al. Quantification of HIV-1 RNA during antiretroviral therapy: Association with viral phenotype and development of resistance. Antivir Ther 1996; 1:246-254.
67. Vidal C, Garcia F, Gatell JM, et al. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral- naive HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:55-60.
68. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4 lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929-938.
69. Weiser B, Philpott S, Klimkait T, et al. HIV-1 coreceptor usage and CXCR4- specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22:469-479.
70. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382- 392.
71. Seclen E, Soriano V, Gonzalez MM, et al. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis 2011; 204:139- 144.
72. Lehmann C, Daumer M, Boussaad I, et al. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 2006; 37:300- 304.
73. Briz V, Poveda E, Gonzalez MD, et al. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008; 61:405-410.
74. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: A population dynamical perspective. Trends Microbiol 2005; 13:269-277.
75. Lin YL, Mettling C, Portales P, et al. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling. AIDS 2006; 20:1369-1377.